Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:12 AM ET 10-Q
Financial Results Nixxy, Inc. NIXX

Nixxy Q3 2026 Results: Net Loss of $2.12M, Loss Narrows

Nixxy, Inc. reported a net loss of $3.88 million for the nine months ended September 30, 2026, an improvement from the $11.00 million loss in the prior year period. Revenue grew significantly to $74.51 million for the nine months, though the company continues to operate with a working capital deficit and an accumulated deficit of $117.68 million.

Key figure
Net loss $2.12M
7:11 AM ET 10-Q
Financial Results Invivyd, Inc. IVVD

Invivyd Q3 2026 Results: Net Loss of $33.5M, Loss Widens

Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.

Key figure
Net loss $33.5M
7:10 AM ET 8-K
Financial Results Prelude Therapeutics Inc PRLD

Prelude Therapeutics Financial Results

Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.

“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”

Kris Vaddi, Ph.D., Chief Executive Officer of Prelude
7:09 AM ET 8-K
Financial Results Invivyd, Inc. IVVD

Invivyd Financial Results

Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.

Term
Q3 2026

“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”

Marc Elia, Chairman and Chief Executive Officer

“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”

Bill Duke, Chief Financial Officer
7:08 AM ET Form 4
Insider Selling ExlService Holdings, Inc. EXLS

ExlService Holdings Chairman & CEO Rohit Kapoor Sells $4.32M of Stock

Rohit Kapoor, Chairman & CEO, sold 100,000 shares of ExlService Holdings, Inc. at $43.24 a share, worth $4.32M in total on Nov 12, 2026. Shares held after the trade: 565,925 (-15.0%).

Value
$4.32M
Shares
100,000
Price
$43.24
Role
Chairman & CEO
Holding change
-15.0%
Trade date
Nov 12, 2026
7:06 AM ET 10-Q
Financial Results Lexeo Therapeutics, Inc. LXEO

Lexeo Therapeutics Q3 2026 Results: Net Loss of $38.3M, Loss Widens

Lexeo Therapeutics reported total assets of $243.9 million as of September 30, 2026, a decrease from $268.7 million at year-end 2025. The company maintains a strong liquidity position with $90.2 million in cash and cash equivalents and $104.6 million in current U.S. Treasury securities to fund its ongoing clinical development of LX2006 and LX2020.

Key figure
Net loss $38.3M
7:06 AM ET 8-K
Capital Raise InspireMD, Inc. NSPR

InspireMD Capital Raise of $37.5M

InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.

Value
$37.5M
Counterparty
Lake Street Capital Markets, LLC
7:06 AM ET 8-K
Financial Results AirJoule Technologies Corp. AIRJ

AirJoule Technologies Financial Results

AirJoule Technologies reported Q3 2026 results, highlighting the completion of its BitSink acquisition and the delivery of its first AirJoule Prime system to a Data4 data center in France. The company also appointed Timothy N. White, an executive from Carrier Global Corporation, to its board of directors.

Term
Q3 2026

“This quarter marks an important step in AirJoule Technologies’ evolution. We expanded our commercial capabilities through the acquisition of BitSink, strengthened our market access through partnerships like Kubota, and sharpened our AirJoule product roadmap around our two highest-value platforms: Prime for water generation and Core DH for dehumidification.”

Matt Jore, Founder and Chief Executive Officer

“BitSink’s $15 million in signed purchase orders provides greater near-term revenue visibility, while our AirJoule products are moving through a more defined path to commercialization. We are deploying systems in customer environments, measuring real-world performance, and working to validate the economics that will support broader adoption.”

Matt Jore, Founder and Chief Executive Officer
7:06 AM ET 8-K
Financial Results Xtant Medical Holdings, Inc. XTNT

Xtant Medical Holdings Financial Results

Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.

Term
Q3 2026

“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”

Stavros Vizirgianakis, Chairman of the Board

“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”

Stavros Vizirgianakis, Chairman of the Board
7:06 AM ET 8-K
Financial Results Cypherpunk Technologies Inc. CYPH

Cypherpunk Technologies Financial Results

Cypherpunk Technologies reported its Q3 2026 financial results, highlighted by the launch of its Zcash mining operations which generated $9.9 million in revenue from 8,967.29 ZEC mined. The company expanded its treasury to 341,858.75 ZEC, representing approximately 2.01% of the circulating supply, following its acquisition of a mining fleet from Moria Mining.

Term
Q3 2026

“The launch of Cypherpunk Mining in August was transformative, as it enabled the production of ZEC alongside our purchases and contributes to the security of the Zcash network. In the first six weeks of operation, our fleet earned 8,967.29 ZEC as a result of an exceptional 95% uptime, all of which was added to our treasury in a momentous third quarter for the company.”

Douglas E. Onsi, President and Chief Executive Officer

“The quarter marked a major milestone for Cypherpunk, and we are already planning for significant continued growth. We intend to increase our overall hashrate through additional equipment purchases with the goal of representing approximately 25% of the total Zcash network over time.”

Will McEvoy, Chief Investment Officer
7:03 AM ET 8-K
Clinical Trial Data Lexeo Therapeutics, Inc. LXEO

Lexeo Therapeutics Clinical Trial Data

Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.

“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”

R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
7:03 AM ET 8-K
M&A Deal InMed Pharmaceuticals Inc. MTRI

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.

Counterparty
Mentari Therapeutics, Inc.
7:02 AM ET 10-Q
Financial Results Xtend AI Robotics, Inc. XTND ▶ Call

Xtend AI Robotics Q3 2026 Results: Net Loss of $44.6M, Loss Widens

Xtend AI Robotics, Inc. filed its 10-Q for the quarter ended September 30, 2026, following its recent merger with JFB Construction Holdings. The company reports a history of operating losses and limited revenue, focusing on the integration of its AI-driven robotics software across third-party unmanned platforms.

Key figure
Net loss $44.6M
7:01 AM ET 8-K
Financial Results Elauwit Connection, Inc. ELWT

Elauwit Connection Financial Results

Elauwit Connection reported Q3 2026 financial results featuring a 104% sequential revenue increase to $5.6 million, driven by a ramp in construction activity. Key growth indicators showed strength as billed units rose 140% year-over-year and monthly recurring revenue (MRR) grew 66% to $539,000.

7:01 AM ET 8-K
Leadership Change Bruker Corp BRKR

Bruker Leadership Change

Bruker Corporation has appointed Dr. Eicke Latz to its Board of Directors, effective January 1, 2027, expanding the board to twelve members. Dr. Latz is a physician-scientist and biopharma entrepreneur who currently serves as the Scientific Director of the German Rheumatology Research Center. Additionally, the Board declared a quarterly cash dividend of $0.05 per share payable on January 7, 2027.

7:01 AM ET 8-K
Financial Results Instil Bio, Inc. TIL

Instil Bio Financial Results

Instil Bio reported third quarter 2026 financial results, highlighting a cash position of $67.1 million which is expected to fund operations through 2027. The company is transitioning to an asset-focused development model through subsidiaries while reporting a significantly narrowed net loss compared to the prior year period.

Term
Q3 2026
7:01 AM ET 8-K
Investor Presentation Minerva Neurosciences, Inc. NERV

Minerva Neurosciences Investor Presentation

Minerva Neurosciences hosted a Key Opinion Leader (KOL) event and filed an updated investor presentation regarding roluperidone, its product candidate for schizophrenia. The filing includes a revised transcript of the event to clarify that regulatory counsel's expressions of confidence regarding FDA approval were personal opinions and not assurances of future regulatory decisions.

7:01 AM ET 8-K
Stock Buyback StandardAero, Inc. SARO

StandardAero Announces $350M Stock Buyback

StandardAero entered into an accelerated share repurchase (ASR) agreement with Morgan Stanley to buy back $350 million of its common stock. To fund the transaction and other corporate purposes, the company also secured a $600 million incremental senior secured term loan B facility. The buyback is part of a larger $1.0 billion share repurchase program authorized by the board.

Value
$350M
Counterparty
Morgan Stanley & Co. LLC
7:01 AM ET Form 4
Insider Buying Hornbeck Offshore Services, Inc. HOS

Hornbeck Offshore Services President & CEO Todd M. Hornbeck Buys $500K of Stock

Todd M. Hornbeck, President & CEO, bought 85,912 shares of Hornbeck Offshore Services, Inc. at $5.82 a share, worth $500K in total on Nov 13, 2026. Shares held after the trade: 6,036,426 (+1.4%).

Value
$500K
Shares
85,912
Price
$5.82
Role
President & CEO
Holding change
+1.4%
Trade date
Nov 13, 2026
6:58 AM ET 8-K
Financial Results Vycor Medical Inc VYCO

Vycor Medical Financial Results

Vycor Medical reported Q3 2026 revenue of $0.41M, a 19% decrease year-over-year, primarily due to higher-than-normal bulk orders in the prior year period. Despite the revenue decline, the company maintained a high gross margin of 85% and reported a nine-month operating profit of $80,083.

Term
Q3 2026
6:58 AM ET 8-K
Capital Raise T1 Energy Inc. TE

T1 Energy Capital Raise

T1 Energy Inc. entered into an equity distribution agreement to establish an at-the-market (ATM) offering program for the sale of up to $100 million of its common stock. The company intends to use the proceeds to fund the construction of Phase 1 of its G2_Austin infrastructure and for general corporate purposes. Roth Capital Partners will serve as the sales agent and receive a commission of up to 3.00% of gross sales proceeds.

Counterparty
Roth Capital Partners, LLC
6:51 AM ET 10-Q
Financial Results Cypherpunk Technologies Inc. CYPH

Cypherpunk Technologies Q3 2026 Results: Turns Profitable, Net Income $306M

Cypherpunk Technologies reported a significant turnaround for the nine months ended September 30, 2026, with net income of $268.2 million compared to a net loss of $35.4 million in the prior year, primarily driven by a $299.3 million gain from the change in fair value of an embedded derivative. The company also launched mining operations, generating $9.9 million in revenue, and significantly strengthened its balance sheet through ATM stock sales and digital asset appreciation.

Key figure
Net income $306M
6:50 AM ET Form 4
Insider Buying Target Hospitality Corp. TH

Target Hospitality Chief Commercial Officer Troy C. Schrenk Buys $250K of Stock

Troy C. Schrenk, Chief Commercial Officer, bought 21,402 shares of Target Hospitality Corp. at $11.43 to $12.08 a share (average $11.68) in 2 transactions, worth $250K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 238,397 (+5.8%).

Value
$250K
Shares
21,402
Average price
$11.68
Role
Chief Commercial Officer
Holding change
+5.8%
Trade date
Nov 12, 2026 to Nov 13, 2026
6:50 AM ET 8-K
Shareholder Meeting Cardinal Health Inc CAH

Cardinal Health Shareholder Meeting

Cardinal Health held its 2026 Annual Meeting of Shareholders on November 12, 2026, where shareholders elected 11 directors to the board. Additionally, shareholders approved the executive compensation plan (say-on-pay) and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2027.

6:48 AM ET 10-Q
Financial Results Blackstone Digital Infrastructure Trust Inc. BXDC ▶ Call

Blackstone Digital Infrastructure Trust Q3 2026 Results: Net Income $15.6M

Blackstone Digital Infrastructure Trust Inc. completed its IPO in May 2026, raising approximately $1.9 billion in net proceeds to invest in data center properties. As of September 30, 2026, the company had not yet purchased any investments, reporting a net income of $22.7 million for the nine months ended primarily driven by interest income on cash holdings.

Key figure
Net income $15.6M
6:47 AM ET 8-K
M&A Deal NorthWestern Energy Group, Inc. NWE

NorthWestern Energy Group M&A Deal with Black Hills Corporation

NorthWestern Energy Group, Inc. completed its merger with Black Hills Corporation, becoming a wholly owned subsidiary of Black Hills. NorthWestern shareholders received 0.98 shares of Black Hills common stock for each share of NorthWestern common stock held. Following the closing, NorthWestern common stock will be delisted from the Nasdaq Stock Market.

Counterparty
Black Hills Corporation
6:47 AM ET 8-K
Stock Buyback Insight Enterprises Inc NSIT

Insight Enterprises Announces $400M Stock Buyback

Insight Enterprises announced that its Board of Directors has authorized a new $400.0 million stock repurchase program. This new authorization is in addition to approximately $36.5 million remaining under previous buyback programs as of November 4, 2026.

Value
$400M
6:47 AM ET 8-K
M&A Deal Black Hills Corp BKH

Black Hills M&A Deal with NorthWestern Energy Group, Inc.

Bright Horizon Energy Corporation (formerly Black Hills Corp.) completed its all-stock merger with NorthWestern Energy Group, Inc. on November 13, 2026. NorthWestern shareholders received 0.98 shares of the combined company for each share held, and the new entity began trading on the NYSE under the ticker symbol 'HZN'.

Counterparty
NorthWestern Energy Group, Inc.
6:47 AM ET 8-K
Financial Results Blackstone Digital Infrastructure Trust Inc. BXDC

Blackstone Digital Infrastructure Trust Financial Results

Blackstone Digital Infrastructure Trust (BXDC) reported its third-quarter 2026 financial results, featuring net income of $15.6 million and FFO of $0.15 per share. The company also highlighted its inaugural investment in thirteen newly constructed data centers through a sale-leaseback transaction with Amazon.

Counterparty
Amazon

“Today marks an important milestone for BXDC with our inaugural investment in thirteen newly constructed data centers across two campuses through a sale-leaseback with Amazon. We believe this transaction delivers highly compelling risk-adjusted returns and establishes a strong foundation for long-term shareholder value creation. Importantly, it highlights our ability to source unique investment opportunities as well as the evolution of our investible universe, as the hyperscaler sale-leaseback channel doubles our total addressable market. We believe BXDC is exceptionally well-positioned to capitalize on this growing opportunity set.”

Nick Pell, Chief Executive Officer and President

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.